{"product_id":"coherus-business-model-canvas","title":"Coherus Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus Biosciences: Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Coherus Biosciences's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances for Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences actively cultivates strategic alliances with other pharmaceutical and biotech firms. These partnerships are crucial for the co-development and rigorous evaluation of innovative cancer treatments, specifically to broaden the approved uses and enhance the effectiveness of their immuno-oncology portfolio.\u003c\/p\u003e\n\u003cp\u003eA key aspect of these collaborations involves testing LOQTORZI, Coherus's flagship immuno-oncology product, in combination with emerging, high-potential cancer therapies. For instance, in 2024, Coherus announced a collaboration to explore LOQTORZI alongside a novel small molecule inhibitor, aiming to achieve synergistic anti-tumor effects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences actively partners with academic and research institutions to drive innovation in oncology. These collaborations are vital for deepening scientific knowledge, exploring novel therapeutic avenues, and pinpointing promising new targets for cancer treatment. For instance, in 2024, Coherus continued to engage with leading universities and research centers, fostering an environment where cutting-edge discoveries can be translated into potential clinical applications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences relies on Contract Manufacturing Organizations (CMOs) for the crucial production and packaging of its existing drug portfolio and its developing pipeline. These partnerships are vital for maintaining a consistent and compliant supply chain.\u003c\/p\u003e\n\u003cp\u003eThe strategic importance of CMOs is underscored by the resumption of UDENYCA production in late 2024, handled by these third-party manufacturers. This demonstrates Coherus’s ongoing need for external manufacturing expertise to ensure product availability and meet stringent regulatory requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Commercialization Partners (Historical\/Divested Biosimilars)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences has historically relied on key partnerships for the distribution and commercialization of its biosimilar products.  These collaborations were crucial for market access in specific geographic regions.\u003c\/p\u003e\n\u003cp\u003eA notable example is the partnership with Daiichi Sankyo, which handled the commercialization of Coherus's biosimilar etanercept and rituximab in select Asian markets. While Coherus is strategically shifting away from biosimilars, these past arrangements highlight the importance of distribution networks.\u003c\/p\u003e\n\u003cp\u003eEven with the divestment from biosimilars, any residual distribution agreements or transitional arrangements for existing biosimilar assets remain relevant to the business model. These partnerships allowed Coherus to leverage established commercial infrastructure.\u003c\/p\u003e\n\u003cp\u003eThe company's strategic pivot means that future partnerships will likely focus on its oncology pipeline, rather than the historical biosimilar distribution arrangements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences actively cultivates relationships with healthcare providers and networks, including hospitals, specialized oncology clinics, and integrated delivery networks. These collaborations are fundamental to securing market access for its biosimilar and innovative oncology therapies, driving product adoption, and collecting crucial real-world evidence to support their efficacy and value proposition.\u003c\/p\u003e\n\u003cp\u003eDirect engagement with healthcare professionals, especially oncologists, forms the bedrock of Coherus' sales and marketing initiatives. This focused approach ensures that clinicians are well-informed about the benefits and appropriate use of Coherus' treatments. For instance, in 2024, Coherus continued to expand its commercial reach, aiming to capture a significant share of the oncology biosimilar market, which is projected to grow substantially in the coming years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital and Clinic Partnerships:\u003c\/strong\u003e Coherus collaborates with a wide array of healthcare institutions to facilitate patient access to its oncology drugs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncologist Engagement:\u003c\/strong\u003e Direct sales force efforts and medical affairs teams focus on educating oncologists about product profiles and clinical data.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReal-World Evidence Generation:\u003c\/strong\u003e Partnerships enable the collection of data demonstrating product performance and patient outcomes in clinical practice.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access Strategy:\u003c\/strong\u003e Collaborations are key to navigating payer landscapes and securing formulary placement for Coherus' therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations Drive Oncology Innovation and Supply Chain Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' key partnerships are vital for its strategic focus on oncology, particularly with other biotech firms for co-development and clinical trials of its immuno-oncology product, LOQTORZI.  These collaborations, including a 2024 agreement to test LOQTORZI with a novel small molecule inhibitor, aim to enhance anti-tumor effects and expand treatment options.\u003c\/p\u003e\n\u003cp\u003eThe company also leverages partnerships with academic and research institutions to advance scientific understanding and identify new therapeutic targets, a strategy actively pursued in 2024. Furthermore, Coherus relies on Contract Manufacturing Organizations (CMOs) for production, as demonstrated by the 2024 resumption of UDENYCA manufacturing by these external partners, ensuring supply chain integrity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eFocus Area\u003c\/th\u003e\n\u003cth\u003e2024 Impact\/Activity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\/Pharma Collaborations\u003c\/td\u003e\n\u003ctd\u003eOncology Drug Co-development (e.g., LOQTORZI combinations)\u003c\/td\u003e\n\u003ctd\u003eAnnounced collaboration with a novel small molecule inhibitor for synergistic effects.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Research Institutions\u003c\/td\u003e\n\u003ctd\u003eScientific Knowledge Advancement, Target Identification\u003c\/td\u003e\n\u003ctd\u003eContinued engagement with universities for translating discoveries into clinical applications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing Organizations (CMOs)\u003c\/td\u003e\n\u003ctd\u003eDrug Production and Packaging\u003c\/td\u003e\n\u003ctd\u003eResumed UDENYCA production, highlighting reliance for supply chain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' business model focuses on developing and commercializing high-quality, affordable biosimil products, targeting physicians and payers with a value-driven approach to healthcare access.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes efficient manufacturing, strategic partnerships, and a robust sales and marketing infrastructure to capture market share in the growing biosimilar landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' Business Model Canvas acts as a pain point reliever by offering a clean and concise layout ready for boardrooms or teams to quickly identify core components and understand their strategy for bringing biosimil products to market.\u003c\/p\u003e\n\u003cp\u003eThis model saves hours of formatting and structuring, providing a shareable and editable snapshot for team collaboration and adaptation, effectively addressing the pain of complex strategy communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Innovative Oncology Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' core activity is the relentless pursuit of groundbreaking immuno-oncology treatments.  This involves not only pushing forward existing promising therapies like LOQTORZI into new areas of cancer treatment but also nurturing a robust pipeline of future innovations, including promising candidates such as casdozokitug and CHS-114.\u003c\/p\u003e\n\u003cp\u003eA critical component of this R\u0026amp;D is the meticulous execution of clinical trials. These trials span multiple phases, from early-stage safety assessments to larger-scale efficacy studies, ensuring that new therapies meet rigorous scientific and regulatory standards before they can reach patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Marketing of Approved Oncology Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' key activities include the commercialization and marketing of its approved oncology products, most notably LOQTORZI, a PD-1 inhibitor.  The company is actively focused on maximizing LOQTORZI's revenue potential within its approved indications, such as nasopharyngeal carcinoma.\u003c\/p\u003e\n\u003cp\u003eTheir sales and marketing approach is built around direct engagement with healthcare professionals, ensuring targeted outreach and education about LOQTORZI's benefits. This direct interaction is crucial for driving adoption and market penetration.\u003c\/p\u003e\n\u003cp\u003eFor the first quarter of 2024, Coherus reported net product sales of $72.9 million, with LOQTORZI contributing $26.6 million in its initial launch period. This demonstrates early traction for the product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Regulatory Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences actively manages the entire lifecycle of its clinical trials, a crucial activity for bringing new therapies to market. This involves meticulous planning, execution, and rigorous data analysis to ensure the safety and efficacy of their drug candidates.\u003c\/p\u003e\n\u003cp\u003eNavigating complex regulatory landscapes is paramount. Coherus's commitment to regulatory affairs ensures compliance with agencies like the U.S. Food and Drug Administration (FDA), facilitating the progression of their drug candidates through the development pipeline and toward potential market authorization.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Coherus continued to advance its pipeline, with key clinical trial milestones being reported across its portfolio. For instance, their work on UDENYCA (pegfilgrastim-cbkn) and CIMERLI (biosimilar trastuzumab-qyjp) demonstrates their ongoing engagement in managing and progressing late-stage clinical development and regulatory submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management and Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences actively manages and protects its intellectual property, a critical component for its oncology pipeline and established products. This strategy is vital for securing its competitive edge in the biopharmaceutical market.\u003c\/p\u003e\n\u003cp\u003eThe company diligently pursues patent filings for new discoveries and vigorously defends its existing patent portfolio. This proactive approach ensures the exclusivity of its innovative therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Filings:\u003c\/strong\u003e Coherus continues to file new patents to cover its ongoing research and development in oncology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Defense:\u003c\/strong\u003e The company actively monitors and defends its issued patents against potential infringements, safeguarding its market position.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Strength:\u003c\/strong\u003e A robust intellectual property portfolio is key to Coherus's valuation and its ability to attract investment and partnerships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development and Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences actively engages in strategic business development by divesting non-core biosimilar assets to sharpen its focus. For instance, the divestiture of UDENYCA (pegfilgrastim-cbqv) and their CIMERLI (biosimilar ranibizumab-eqni) and YUSIMRY (biosimilar adalimumab-aqv) biosimilar franchises were key moves. This strategy aims to bolster their financial health and concentrate resources on their promising oncology pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Divestitures:\u003c\/strong\u003e Coherus completed the divestiture of its UDENYCA and CIMERLI biosimilar franchises to Syngene International Limited in 2024, generating significant upfront payments and potential milestone payments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Prioritization:\u003c\/strong\u003e This divestiture allowed Coherus to streamline its operations, focusing capital and management attention on advancing its late-stage oncology assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Enhancement:\u003c\/strong\u003e The transactions are designed to improve Coherus's balance sheet and provide runway for ongoing clinical development and potential future acquisitions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture Opportunities:\u003c\/strong\u003e The company continues to evaluate in-licensing and out-licensing opportunities to complement its existing portfolio and drive long-term growth in the oncology space.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Oncology Focus: Pipeline, Commercialization, Divestitures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoherus Biosciences' key activities revolve around advancing its oncology pipeline, particularly with immuno-oncology therapies like LOQTORZI. This involves rigorous clinical trial execution across multiple phases to ensure safety and efficacy, alongside meticulous management of the entire trial lifecycle from planning to data analysis.\u003c\/p\u003e\n\u003cp\u003eCommercialization and marketing of approved products, such as LOQTORZI for nasopharyngeal carcinoma, are central. This includes direct engagement with healthcare professionals to drive product adoption and market penetration. Furthermore, Coherus actively manages its intellectual property through patent filings and defense, safeguarding its competitive edge.\u003c\/p\u003e\n\u003cp\u003eStrategic business development, including the divestiture of non-core biosimilar assets, is another crucial activity. These divestitures, such as the 2024 sale of UDENYCA and CIMERLI franchises, aim to enhance financial health and concentrate resources on their promising oncology pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2024 Data\/Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Pipeline Advancement\u003c\/td\u003e\n\u003ctd\u003eDeveloping and advancing novel immuno-oncology treatments.\u003c\/td\u003e\n\u003ctd\u003eContinued progress on LOQTORZI, casdozokitug, and CHS-114.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Execution\u003c\/td\u003e\n\u003ctd\u003eManaging all phases of clinical trials for drug candidates.\u003c\/td\u003e\n\u003ctd\u003eOngoing trials for multiple oncology assets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Commercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing and sales of approved products like LOQTORZI.\u003c\/td\u003e\n\u003ctd\u003eQ1 2024 LOQTORZI sales of $26.6 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property Management\u003c\/td\u003e\n\u003ctd\u003eFiling and defending patents for its therapies.\u003c\/td\u003e\n\u003ctd\u003eActive patent filings to protect R\u0026amp;D discoveries.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Divestitures\u003c\/td\u003e\n\u003ctd\u003eSelling non-core biosimilar assets to focus on oncology.\u003c\/td\u003e\n\u003ctd\u003eDivestiture of UDENYCA and CIMERLI franchises in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis preview showcases the actual Coherus Biosciences Business Model Canvas, offering a transparent glimpse into the comprehensive analysis you will receive. Upon purchase, you gain full access to this exact document, meticulously detailing Coherus's strategic framework, value proposition, customer segments, and revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611325546873,"sku":"coherus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/coherus-business-model-canvas.png?v=1754755371","url":"https:\/\/growthsharematrix.com\/products\/coherus-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}